GRG. S. Rozanova

G. S. Rozanova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


G. S. Rozanova has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Analysis of structure and dynamics of the anti-asthma drugs market in the Russian Federation: retail and hospital segments

    by G. S. Rozanova, I. V. Zhamborova, R. A. Bontsevich

    Anti-asthma drugs occupy an important place in the pharmacotherapy of chronic respiratory diseases, which determines the need for a comprehensive analysis of this segment of the pharmaceutical market. The purpose of this study was to identify quantitative and structural patterns in the development of the retail and hospital segments of the R03 drug market based on recent analytical data. The information base included analytical materials from RNC Pharma and public procurement data for 2025, processed using comparative, structural, and dynamic analysis methods, as well as elements of pharmacoeconomic evaluation. It was found that in 2025 both retail and hospital market segments demonstrated steady growth, accompanied by an increase in consumption volumes and value indicators. Strengthening of domestic manufacturers’ positions was identified, especially in the hospital segment, along with significant price differentiation between domestic and imported drugs. The retail market was characterized by a high level of concentration combined with a wide range of product offerings. Additionally, pronounced seasonality of demand and signs of transformation in consumer behavior were observed in early 2026. The obtained results indicate active import substitution processes and changes in consumption patterns, which require further study in terms of accessibility and effectiveness of pharmacotherapy.

  • Chronic Obstructive Pulmonary Disease: Economic Burden in Russia and European Countries (Review)

    by G. S. Rozanova, G. I. Zavitkevich, R. A. Bontsevich, M. L. Maximov

    INTRODUCTION. Chronic obstructive pulmonary disease (COPD) is a leading cause of death and significant economic losses for the healthcare system. While there is a trend towards decreasing COPD incidence in Europe, Russia saw the incidence increase by 5%, and the economic burden rose from 0.20% to 0.34% of GDP in 2022–2023. International and nationwide best practices necessitate a further analysis to identify the ways of reducing financial burden on the Russian healthcare system. AIM. This study aimed to identify and evaluate feasibility for the most effective ways to reduce the financial burden when managing COPD patients in the Russian Federation. DISCUSSION. Key differences in COPD epidemiology and cost structure were identified between Russia and EU countries. In the European Union (2001–2019), COPD incidence decreased among men (–9.7%) and increased among women (+4.3%) due to higher smoking rates. In Russia, the incidence continued to grow (+5%), while the mortality remained high (26% of the total death causes). In the EU, main direct costs were attributed to inpatient care (35–64%) and drug therapy (~25%), while the share of indirect costs reached 61–83%. Russian cost structure differed: the share of indirect costs was 92.6%, while among the direct costs, 76.1% was attributed to medicines supply, and only 18.7% covered inpatient care. Effective burden reduction included: smoking cessation (reduced exacerbation risk by 39.7%; hazard ratio 0.65 for abstinence >10 years); prophylactic vaccinations (reduced hospitalizations by 50%, while vaccine refusal increased mortality 162-fold); modern pharmacotherapy (triple therapy: long-acting anticholinergic agents + long-acting beta2-agonists + inhaled glucocorticoids, reduced exacerbation frequency by 24% and mortality by 49%), and pulmonary rehabilitation (OR for hospital readmissions 0.44) still presented poorly in Russia (~10%). CONCLUSIONS. To reduce COPD economic burden in the Russian Federation, it is necessary to increase the coverage with preventive measures (tobacco control programs, immunization), develop pulmonary rehabilitation programs using digital technologies, implement modern pharmacotherapy regimens, and improve physicians’ expertise via continuing medical education.


  • Pharmacotherapy of chronic obstructive pulmonary disease: Assessment of knowledge of doctors and senior students. Results of the ASCO III study

    by R. A. Bontsevich, G. I. Zavitkevich, G. A. Batishcheva, V. A. Nevzorova, O. V. Tsygankova, G. S. Rozanova, G. G. Ketova, I. M. Martynenko, I. F. Krotkova, E. Yu. Ebzeeva, et al.

    Introduction. Chronic obstructive pulmonary disease (COPD) is one of the leading causes of mortality worldwide. The global prevalence of COPD is estimated at 10.3%. In Russia, there are more than 4 million patients with COPD, with 40% requiring hospitalization and 14% needing rehospitalization. Such statistics highlight the significance of COPD. Aim. To assess the level of knowledge among physicians and senior medical students regarding COPD pharmacotherapy. Mat erials and methods. This article presents an analysis of data on the knowledge assessment and preferences of specialists and senior medical students regarding COPD pharmacotherapy, obtained during the multicenter ASCO III study conducted between 2019 and 2023. Results. A total of 420 physician questionnaires from 11 regions and 372 student questionnaires from 7 medical universities were analyzed. The average level of correct answers (LCA) was 56.1% among physicians and 41.6% among students (p < 0.001). Respondents demonstrated the best results in questions related to the combination of drugs in a single delivery device. The poorest results were observed in questions regarding the choice of baseline therapy for severe COPD symptoms and the optimal selection of antibacterial agents during disease exacerbations. Correlation analysis of the relationship between “LCA” and “Years of Experience” among physicians revealed a weak inverse correlation between specialists’ knowledge level and their work experience. Conclusions. A relatively low level of knowledge in COPD pharmacotherapy was identified among both physicians and students. Physicians demonstrated significantly better knowledge than students in most areas. According to the authors, there is a need for continued assessment of knowledge in real-world practice and the optimization of both core and supplementary educational activities in this field.


  • Analysis of public procurement of josamycin for 2023–2024

    by I. V. Zhamborova, G. S. Rozanova

    This study is dedicated to a comprehensive analysis of public procurement of the antibiotic josamycin in Russia for the period 2023-2024. Transparency, openness, and competitiveness are generally accepted principles that must be strictly observed to achieve procurement efficiency, i.e. to save budget funds [1]. The research encompasses an assessment of procurement volume dynamics, regional distribution across federal districts, and changes in the consumption structure of various dosage forms of the drug. Particular attention is paid to the analysis of the market share occupied by the originator drug versus generic versions. The study reveals a sharp decline in procurement activity in 2024 and an absolute dominance of the originator brand. The work underscores the importance of the obtained results for planning budgetary expenditures and ensuring the accessibility of drug therapy within the healthcare system. The analysis utilized data from the Unified Information System of public procurement in the Russian Federation (EIS).

  • Analysis of public procurement for triple fixed-dose combinations in patients with COPD and bronchial asthma from 2020 to 2025

    by G. S. Rozanova, I. V. Zhamborova, R. A. Bontsevich

    The article examines the dynamics of the Russian budget market for triple fixeddose combinations used in the treatment of chronic obstructive pulmonary disease (COPD) and bronchial asthma (BA) over the period from 2020 to 2025. It describes the main combinations available on the market. The analysis demonstrates a steady increase in sales volume and gradual growth in the share of new drugs. The study highlights the significance of these medications as universal tools in treating broncho-obstructive syndromes and identifies prospects for further expansion of their employment in clinical practice.